Global drugmakers boost US investments as Trump administration considers major tariffs on imported medicines
Global pharmaceutical manufacturers are accelerating investments in United States production to mitigate potential 100 percent tariffs on imported medicines.
洞察:
The administration of Donald Trump donald trumpis currently considering the implementation of a 100 percent tariff on imported branded and patented medicines, a move that is prompting a massive shift in how the pharmaceutical manufacturing sector operates within the United States 
US. While the policy remains under discussion and has not yet been implemented, enforcement is expected to be delayed for companies that commit to significant investments in domestic manufacturing. This trade policy uncertainty has already triggered more than $500 billion in collective investment commitments from global pharmaceutical giants looking to secure their supply chains.
US. While the policy remains under discussion and has not yet been implemented, enforcement is expected to be delayed for companies that commit to significant investments in domestic manufacturing. This trade policy uncertainty has already triggered more than $500 billion in collective investment commitments from global pharmaceutical giants looking to secure their supply chains.A select group of major players has already moved to secure specific protections. Pfizer Inc. reached a deal on September 30 to invest $70 billion in research, development, and domestic manufacturing, receiving a three-year tariff exemption in return. Pfizer Inc.and AstraZeneca PLC , which is based in the United Kingdom 
GBand Sweden 
SE, secured multi-year tariff exemptions through pricing deals and commitments to the TrumpRx.gov platform. AstraZeneca PLCfurther announced it will invest $50 billion in United Statesmanufacturing by 2030, including a new drug substance facility in Virginia.
GBand Sweden SE, secured multi-year tariff exemptions through pricing deals and commitments to the TrumpRx.gov platform. AstraZeneca PLCfurther announced it will invest $50 billion in United Statesmanufacturing by 2030, including a new drug substance facility in Virginia.
